Company intelligence / Profile preview

Foxcroft Therapeutics

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Foxcroft Therapeutics is a pre-clinical stage biotechnology company dedicated to discovering and developing small molecule medicines for oncology. The company focuses on targeting transcription factors, a class of proteins historically considered "undruggable," to treat various forms of cancer. Led by experienced biotech executive Michael Gilman, Foxcroft utilizes a specialized platform to identify and optimize compounds that can modulate gene expression at the transcriptional level. The firm is backed by prominent life science investors and is currently advancing its internal pipeline toward candidate selection.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Foxcroft Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foxcroft Therapeutics.

Explore the full profile